With clinical records, patient samples and images in the millions, the diagnostics and data company is betting precision medicine can go multimodal

Plus: Jeffrey Sevigny named CMO of Rapport, and updates from Garuda, Metis, Ovid and more

BioCentury’s roundup of translational innovations also includes causal biology for a heart condition, and the biological foundational model Evo 2

BioCentury’s roundup of translational innovations also includes a human hypothalamus atlas from Novo and collaborators, and four papers with links to newcos

70% of new precision medicines approved by FDA in past three years were not sponsored by major pharmas

Decisions include Ozempic for CKD, a non-opioid painkiller, AZ-Daiichi’s TROP2 ADC, and an allogeneic T cell therapy

BioCentury’s analysis of the SITC, ASH abstracts highlights progress in bicistronic and tandem CAR Ts

Oligo delivery to the kidney, and two emerging use cases for T cell engagers, each get newcos; most with mega-